Approval · Notice of Compliance 20498 · 2018
NIMENRIX: Notice of Compliance 20498
Issued February 19, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20498
- Date
- February 19, 2018
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Nimenrix is indicated for the active immunization of individuals from 6 weeks to 55 years of age against invasive meningococcal diseases caused by neisseria meningitidis serogroups a, c , w-135 and y. revised product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NIMENRIX | Not yet assigned | — |
Medicinal ingredients
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135 5 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A 5 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C 5 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y 5 MCG per 0.5ML
- TETANUS TOXOID 44 MCG per 0.5ML